Dear colleagues,

We are writing to inform you of a new clinical trial that is currently recruiting patients in case it is of your interest:

LuPARPed clinical trial: ‘Single-arm open-label phase II study in children and adolescents of 177Lu-DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for the treatment of recurrent or relapsed solid tumours expressing somatostatin receptor (SSTR) (LuPARPed)’.

We attach a summary of the clinical trial. Among the tumors that can take up somatostatin, at least stand out: high-risk neuroblastoma, medulloblastoma, meningioma, high-grade glioma, neuroendocrine tumors, pheochromocytoma and paraganglioma. However, any tumor that uptakes somatostatin (detected by a 68Ga-DOTATOC) would be eligible for the trial. Patients older than 3 years can be included, with no upper age limit (as long as they were diagnosed before 19 years of age).

Do not hesitate to contact us in case of any questions.

All the best!

María Ortiz Campos